Health & Biotech
The biggest company you’ve never head of
Race submits key ethics application for phase I cancer trial
US reimbursement rate set for Lumos point-of-care respiratory test
Health Check: Biotech’s forgotten tortoises pick up the pace as sector emerges from two-year slump
Dr Boreham’s Crucible: Will ditching its baggage help this pancreatic cancer-targeting outfit soar?
Could Trump’s second act boost these ASX psychedelic stocks?
Health Check: Pro Medicus founders cashed up for the festive season
Imagion set to improve cancer detection through molecular MRI
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
Biocurious: Armed with a lucky payment number, Control Bionics plots its US expansion
ReNerve inks deal to expand nerve-repair product in Hong Kong and Macau
Health Check: Let there be light (therapy). Invion up 160pc on skin cancer trial news
Orthocell leaps closer to FDA approval after pivotal nerve-repair product study success
Health Check: No sign of frayed nerves as Orthocell girds for US approval
Scott Power: Which ASX healthcare stock has soared 30pc this week?
Tryptamine completes psilocin-based IV-infusion study in obese subjects
Health Check: It’s goodbye to ugly grey ‘gob filler’ as SDI’s aesthetic alternative gains traction
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
